Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin

Blefaroespasmo e edema periorbitário após mesilato de imatinibe: melhora com toxina botulínica

Hélio A. G. TEIVE1,2, Francisco M. B. GERMINIANI1, Renato P. MUNHOZ3, Carlos Henrique F. CAMARGO2

A 71-year-old man on treatment for chronic myeloid leukemia with imatinib mesylate presented with bilateral severe periorbital edema, including his eyelids, later progressing to blepharospasm (Figure A), and was referred to our Botulinum Toxin Outpatient Clinic two years ago. Hematological routine examinations, head and sinuses CT, brain MRI and CSF studies were normal. No treatment for dystonia had been done previously, including botulinum toxin. Botox® (70U of onabotulinumtoxinA, Allergan Inc., Irvine, CA, USA) was used for treatment of blepharospasm, with partial improvement (Figure B).

Periorbital edema is a fairly common side effect of imatinib mesylate1; however, the association with blepharospasm, and the treatment with botulinum toxin, has not been published2. When the normal protective blink reflex becomes excessive, the ocular surface may be traumatized. The forceful and excessive eyelid blinking is not only debilitating but also results in further microtrauma to the ocular surface, further exacerbating the disease process. Patients with these conditions can present with chronic pain, photophobia, foreign body sensation, and secondary blepharospasm. Therefore, blepharospasm may be a symptom of ocular surface disease, and the use of botulinum toxin may be beneficial3.

Figure. Patient with severe periorbital edema associated with blepharospasm, secondary to treatment with imatinib mesylate. Imaging before (A) and after (B) botulinum toxin use. (With the patient’s permission).

1Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Clínica Médica, Serviço de Neurologia, Setor de Distúrbios do Movimento, Curitiba PR, Brasil;
2Universidade Federal do Paraná, Hospital de Clínicas, Programa de Pós-Graduação em Medicina Interna e Ciências da Saúde, Curitiba PR, Brasil;
3University of Toronto, Toronto Western Hospital, Gloria and Morton Shulman Movement Disorders Centre, Toronto,ON, Canada.

Hélio Afonso Ghizoni Teive https://orcid.org/0000-0002-4045-1178; Francisco Manoel Branco Germiniani https://orcid.org/0000-0001-9494-9759; Renato Puppi Munhoz https://orcid.org/0000-0002-4783-4067; Carlos Henrique Ferreira Camargo https://orcid.org/0000-0002-3533-0347

Correspondence: Hélio A. G. Teive; Rua General Carneiro 1103/102 – Centro; 80060-150 Curitiba PR, Brasil; E-mail: hagteive@mps.com.br

Conflict of interest: There is no conflict of interest to declare.

Received 05 March 2019; Received in final form 03 May 2019; Accepted 03 May 2019.
References

